Marker Therapeutics Business Summary

Marker Therapeutics, Inc. (MRKR) is a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for hematological malignancies and solid tumors. The company’s primary business model centers on the advancement of its proprietary Multi-Antigen Targeted (MAR-T) cell platform, which utilizes non-engineered T cells to recognize multiple tumor-associated antigens simultaneously. Unlike traditional CAR-T therapies, Marker’s approach aims to reduce toxicity and prevent tumor escape. Revenue is currently generated through non-dilutive grant funding, primarily from the Cancer Prevention and Research Institute of Texas (CPRIT) and the National Institutes of Health (NIH), as the company has no commercialized products. Its lead clinical programs include MT-601 for the treatment of lymphoma and pancreatic cancer, and MT-401-OTS for acute myeloid leukemia. Within the competitive landscape, Marker contends with Cardiff Oncology, Coya Therapeutics, and BioXcel Therapeutics, positioning itself as a cost-effective, multi-antigen alternative to complex and high-toxicity engineered cell therapies. The leadership team is anchored by Co-Founder Dr. Juan F. Vera, who serves as Chief Executive Officer, President, Secretary, and Treasurer. Dr. Vera brings over two decades of expertise in adoptive T cell therapy from the Center for Cell and Gene Therapy at Baylor College of Medicine. Key executive support includes Mary Newman, Head of Regulatory Affairs, who possesses 35 years of experience in drug development and regulatory strategy, and Patricia Allison, Head of Clinical Operations. The Board of Directors is chaired by David Eansor, former President of the Protein Sciences Segment at Bio-Techne, and includes Steven Elms, Managing Partner at Aisling Capital, and Kathryn Penkus Corzo, President and COO of bit.bio. Notable institutional backing is provided by NEA Management Company, Blue Owl Capital, and Aisling Capital Management, reflecting strong investor confidence in the company’s non-engineered cellular platform.